6th Annual Immuno-Oncology 360°

6th Annual Immuno-Oncology 360°(IO360?) is organized by The Conference Forum (TCF) and will be held from Feb 26 - 28, 2020 at Crowne Plaza Times Square Manhattan, New York City, New York, United States of America.

Who Should Attend:
The program is designed for all size pharma/biotech companies, academia and investors seeking to enable a patient’s immune system to eradicate cancer.

Large Pharma /Biopharma /Biotech Responsible for:
• Cancer Immunotherapy
• Immuno-Oncology
• R&D Innovation & Strategy
• Clinical R&D
• Business Development
• Preclinical and Translational Research
• Licensing & Commercial Strategy
• Biomarkers and Companion Dx
• Early Stage Collaborations
• Clinical Operations
• Strategic Partnerships
• Medical Affairs
• External R&D

Investment Community:
• Investment Firms
• Banks/Financial Institutions
• Venture Capitals
• Foundation Capital
• Analysts

Academia & Research Organizations Focusing on:
• Immuno-Oncology / Cancer Immunotherapy
• Oncology
• Immunology
• Immunobiology
• Cancer Vaccines
• Adoptive T-Cell Therapy
• Preclinical & Clinical R&D
• Biomarkers & Companion Dx

Solution Providers:
• CROs
• Adaptive Trial Design
• Diagnostic Testing
• Biomarker Software
• Data Analysis/Analytics
• Logistics
• Patient Recruitment
• Consultants

Overview:
IO360?convenes stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers.

Immuno-Oncology 360° delivered three key benefits:
• Access to KOLs driving the science
• Partnership opportunities with all stakeholders in Immuno-Oncology
• Presentations on the latest data affecting the science, clinical and business advancements in Immuno-Oncology

Immuno-Oncology 360° provided 10 plenary sessions over the course of 3 days addressing:
• Discovery / Preclinical Science
• Translational Science & Biomarkers
• Clinical Data Developments
• Clinical Operations
• Imaging Aspects
• Cell Therapy
• Emerging Technologies
• Business Aspects
• Financial & Commercial Implications
• Trends in the Field

Immuno-Oncology 360° reports on the most current data and rapid advancements to help IO stakeholders:
• Be at the forefront of the most relevant research and developments from key leadership who are at the pulse of cancer immunotherapy
• Foster collaboration amongst those working in all aspects of cancer immunotherapy together under one roof
• Partner to expand technology platforms to develop therapeutics at an accelerated rate
• Receive the latest pre-clinical, translational and clinical data from academia and industry
• Create and prioritize strategies targeted toward specific tumor types
• Identify and gain a greater understanding of what assets are available for potential combinations
• Hear from IO clinical trial leaders as they cover trial design, clinical operations, the latest outcomes and lessons learned
• Get key investor and analyst evaluations and insights on the IO landscape, challenges and what’s next
• Learn about biomarker advancements in vaccines, imaging, neoantigen approaches and more
• Obtain coverage on a wide range of emerging technologies

 

Additional details will be posted as soon as information is available.